QPPV.COM KNOWLEDGE ASSESSMENT

Telisotuzumab Vedotin: Classification, Mechanism, Clinical Evidence and Pharmacovigilance

Test your understanding of the concepts covered by Telisotuzumab Vedotin: Classification, Mechanism, Clinical Evidence and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 A safety report identifies a patient treated outside the United States and cites the U.S. accelerated approval as the basis for eligibility. What is the most appropriate regulatory interpretation?

The U.S. approval establishes eligibility in every jurisdiction unless a local authority has issued a restriction. The U.S. indication should not be assumed to apply elsewhere; local authorisation and product information must be checked. Accelerated approval automatically creates a harmonised EU indication. The U.S. indication applies internationally whenever the same companion diagnostic is used.

Question 2 of 10 A clinician asks whether a strong c-Met immunohistochemical result can be replaced by a MET sequencing result when assessing the label-defined biomarker. What is the best response?

The specified protein-expression assay defines the described treatment-selection biomarker; genomic findings should be recorded separately. Any MET mutation or amplification is equivalent to the specified protein-expression threshold. Sequencing is always preferred because immunohistochemistry cannot measure c-Met protein. Either result can be substituted because the companion diagnostic is optional.

Question 3 of 10 For a patient weighing at least 100 kg, which U.S. label dosing detail is described in the article?

The recommended dose is 1.9 mg/kg intravenously every two weeks, with a maximum of 190 mg. The recommended dose is 1.9 mg/kg intravenously every week, with no maximum dose. The recommended dose is fixed at 190 mg for every patient, regardless of weight. The recommended dose is 1.9 mg/kg orally every two weeks.

Question 4 of 10 A benefit–risk review combines spontaneous reports, ongoing clinical-study observations and confirmatory-study results into one undifferentiated evidence set. What is the best corrective action?

Maintain clear separation between routine spontaneous reporting, ongoing studies and the confirmatory obligation, then interpret each in context. Exclude spontaneous reports because accelerated approval depends only on trial data. Treat all sources as equivalent estimates of incidence and combine their event counts. Use only the confirmatory study, because other sources cannot inform pharmacovigilance.

Question 5 of 10 A database reviewer must distinguish suspected drug-induced pneumonitis from infection or tumour progression. Which approach is most appropriate?

Preserve the diagnostic distinction and use the clinical evidence and differential diagnosis rather than coding every respiratory event as pneumonitis. Code every respiratory symptom as confirmed drug-induced pneumonitis because it is a labelled risk. Code all respiratory events as tumour progression unless imaging proves otherwise. Exclude infection from the differential because the patient is receiving an ADC.

Question 6 of 10 A reviewer attributes a patient's peripheral neuropathy to MMAE solely because neuropathy is biologically plausible for this payload. What is the best pharmacovigilance approach?

Accept the mechanism as sufficient proof of causality and omit assessment of other causes. Assess the clinical pattern, timing, functional impact, competing causes and course, using the label definitions rather than mechanism alone. Classify the event as disease progression because the drug is targeted to a tumour antigen. Exclude the event from safety review unless it is accompanied by an infusion reaction.

Question 7 of 10 Which patient profile most closely matches the population described in the U.S. accelerated approval?

An adult with previously treated locally advanced non-squamous NSCLC and high c-Met protein expression meeting the specified test threshold. An adult with untreated squamous NSCLC and a MET fusion, regardless of protein expression. An adult with previously treated non-squamous NSCLC and any detectable c-Met staining, using any assay. A patient with a MET mutation in any solid tumour, regardless of histology or prior treatment.

Question 8 of 10 What is the most appropriate interpretation of the three fatal ILD/pneumonitis cases reported among 168 patients in the LUMINOSITY safety population?

They reinforce the need for prompt evaluation and serious consideration of respiratory events, while remaining trial-specific observations. They establish that all respiratory symptoms during treatment are drug-induced pneumonitis. They prove that the product is contraindicated in every patient with a history of lung disease. They can be disregarded because the overall ILD/pneumonitis frequency was lower than 20%.

Question 9 of 10 A safety reviewer argues that telisotuzumab vedotin should cause toxicity only in c-Met-expressing tumour cells because it is targeted. Which interpretation best reflects its ADC design?

The antibody targets c-Met, but intracellular processing releases an MMAE payload, so systemic payload-related toxicity can occur. The antibody neutralises circulating hepatocyte growth factor, making payload exposure clinically irrelevant. The linker prevents payload release outside tumour cells, so any non-tumour toxicity indicates an unrelated cause. The product is an unconjugated antibody, and its effects are limited to c-Met receptor blockade.

Question 10 of 10 A tumour report describes strong c-Met immunohistochemical staining but no MET gene alteration. Which conclusion is most appropriate for interpreting the label-defined treatment biomarker?

The staining result is a protein-expression finding and should not be reported as a MET mutation, amplification or fusion. Strong staining establishes that a MET gene amplification is present. The absence of a reported gene alteration means the immunohistochemical result is invalid. Protein overexpression and genomic alteration are interchangeable terms for this treatment-selection criterion.

Telisotuzumab Vedotin: Classification, Mechanism, Clinical Evidence and Pharmacovigilance

Cookie Settings